Condition

HIV-1-infection clinical trials and research

• 41Clinical trials
• 40NIH research projects
• 31Countries

Newest HIV-1-infection clinical trials

All recruiting trials (41)

• Weekly long-acting HIV-1 meds switch for people with undetectable virus

  This study tests whether switching to weekly oral long-acting HIV medicines works as well as staying on current daily pills for people with HIV who already have an undetectable viral load.

  Recruiting at 2 sites Phase 2 Gilead Sciences · Ft. Pierce, Florida and 1 other locations · NCT07841990

• HIV in Hong Kong: patterns, transmission, and burden over time

  This project tests how HIV-1 infections in Hong Kong have changed over several years by following newly diagnosed adults and analyzing their subtypes, transmission links, and community burden.

  Recruiting Chinese University of Hong Kong · North Point · NCT07725042

• GS-0415 safety and PK in people with HIV on ART

  This study tests GS-0415 in adults with HIV who are on stable ART to see if it is safe, tolerable, and how the drug behaves in the body.

  Recruiting at 15 sites Phase 1 Gilead Sciences · Los Angeles, California and 15 other locations · NCT07719491

• Gilead study of GS-3242 with Lenacapavir for people starting HIV treatment compared with Biktarvy

  This study tests whether injecting GS-3242 with Lenacapavir can work as well as Biktarvy for people newly starting HIV treatment.

  Recruiting at 19 sites Phase 2/3 Gilead Sciences · Torrance, California and 20 other locations · NCT07708727

• RNA-based vaccine BNT168 safety and immune response in adults with or without HIV

  A first-in-human study tests whether the RNA vaccine BNT168 is safe and can trigger immune responses in adults both with and without HIV.

  Recruiting at 3 sites Phase 1 BioNTech SE · Houston, Texas and 3 other locations · NCT07698600

• Long-acting LEN/TAB/ZAB regimen vs daily HIV meds in adults with suppressed HIV-1

  This study tests whether switching to an injectable, long-acting combination (lenacapavir, teropavimab, zinlirvimab) can keep HIV-1 under control in adults who are already virally suppressed on stable oral therapy.

  Recruiting at 2 sites Phase 3 Gilead Sciences · Berkeley, Michigan and 1 other locations · NCT07683000

• Switch to GS-3242 plus Lenacapavir vs Biktarvy in virologically suppressed people with HIV-1

  This study tests whether switching to GS-3242 with Lenacapavir can maintain viral suppression better than staying on Biktarvy in people living with HIV-1 who are already suppressed.

  Recruiting at 51 sites Phase 2 Gilead Sciences · Phoenix, Arizona and 58 other locations · NCT07645287

• How HIV Treatment Changes Affect Hidden Drug Resistance

  Researchers will see if changing HIV treatment in people with fully suppressed virus reveals hidden drug resistance in proviral DNA.

  Recruiting Chinese University of Hong Kong · Hong Kong, Hong Kong · NCT07643948

• Long-acting cabotegravir and rilpivirine in pregnancy

  This study tests whether long-acting injectable HIV medicines given every 4 weeks are safe and effective for pregnant people with HIV and their babies.

  Recruiting at 4 sites Phase 4 International Maternal Pediatric Adolescent AIDS Clinical Trials Group · La Jolla, California and 9 other locations · NCT07637942

• Dolutegravir/Lamivudine in treatment-naïve pregnant women

  This study tests a two-drug HIV regimen (dolutegravir and lamivudine) in pregnant people who start HIV treatment to see if it keeps the virus suppressed and prevents transmission to the baby.

  Recruiting at 3 sites Phase 4 Fundación Huésped · Ciudad Autónoma de Buenos Aires, Buenos Aires and 9 other locations · NCT07616739

• IAP086 first-in-human single-dose safety study in people with HIV on ART

  This first-in-human trial tests a single dose of IAP086 to see if it is safe and tolerable in adults with HIV who are on stable antiretroviral therapy.

  Recruiting at 2 sites Phase 1 University of North Carolina, Chapel Hill · Chapel Hill, North Carolina and 1 other locations · NCT07596888

• TruPlex rapid test for HIV, Hepatitis B, and syphilis performance and usability

  This project will test whether the TruPlex rapid test can accurately detect HIV, hepatitis B, and syphilis when used by trained healthcare workers on adults getting tested for these infections.

  Recruiting at 3 sites bioLytical Laboratories · Johannesburg, Gauteng and 2 other locations · NCT07563309

• Restarting HIV treatment with a single-pill regimen (B/F/TAF) after a treatment gap

  This study tests whether quickly restarting ART with the single-pill regimen B/F/TAF is safe and effective for people with HIV who have had a treatment interruption of at least 12 weeks.

  Recruiting at 10 sites Phase 4 CAN Community Health · Clearwater, Florida and 9 other locations · NCT07476339

• Restarting HIV treatment with a single-pill regimen (B/F/TAF) after a treatment gap

  This study tests whether quickly restarting ART with the single-pill regimen B/F/TAF is safe and effective for people with HIV who have had a treatment interruption of at least 12 weeks.

  Recruiting at 10 sites Phase 4 CAN Community Health · Clearwater, Florida and 9 other locations · NCT07476339

• Safety and blood activity of the antibody BNT351 in adults with and without HIV

  This study will test whether one dose of the antibody BNT351 is safe, how long it stays in the blood, and if it lowers HIV levels in adults with and without HIV.

  Recruiting at 5 sites Phase 1 BioNTech SE · Chicago, Illinois and 5 other locations · NCT07392372

• Doravirine-based regimen started quickly in HIV-1 infection

  This study tests whether a doravirine/lamivudine/tenofovir combination started rapidly is effective and safe for adults with HIV-1 who have not been treated before.

  Recruiting at 2 sites Phase 4 Fundación Huésped · Ciudad Autonoma de Buenos Aire, Buenos Aires and 1 other locations · NCT07357584

• Single-dose CL-197 capsules for adults with HIV-1 infection

  This trial will test if a single dose of CL-197 capsules is safe and lowers HIV-1 levels in adults who have never taken HIV medications.

  Recruiting Phase 2 Henan Genuine Biotech Co., Ltd. · Beijing · NCT07308782

• Lactation and infant feeding practices among U.S. women living with HIV

  See how pregnant and postpartum women with HIV in the United States make infant feeding choices and what outcomes their infants experience.

  Recruiting at 2 sites International Maternal Pediatric Adolescent AIDS Clinical Trials Group · Los Angeles, California and 10 other locations · NCT07293559

• ICONA Prevention Program for People Using PrEP in Italy

  This program will follow HIV-negative adults in Italy who are starting or already using PrEP to see how well PrEP prevents HIV, how tolerable it is, and what helps or hinders people from staying on it.

  Recruiting at 18 sites Fondazione ICONA · Chieti, Abruzzo and 52 other locations · NCT07186244

• MucoCept-CVN: a vaginal Lactobacillus product to help prevent HIV

  This trial will test whether a modified vaginal Lactobacillus that produces an anti‑HIV protein is safe and can colonize the vagina in healthy premenopausal women.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07181486

• IT-guided HIV screening and prevention in dental clinics

  This project will test whether an electronic alert plus either the usual dental team or an added care navigator helps dental teams offer HIV testing and prevention to dental patients.

  Recruiting Columbia University · New York, New York and 2 other locations · NCT06890988

• Improving coronary blood flow in women with HIV and diabetes or chronic kidney disease

  This study will test whether referring women with HIV and diabetes or chronic kidney disease to a specialist so they can be considered for SGLT2 inhibitor medicine, compared with health education alone, improves blood flow in their hearts.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts · NCT06843902

• Comparing two HIV treatment regimens for maintaining viral suppression

  This study is testing whether two different HIV treatment combinations can help people who have their virus under control stay healthy without using certain types of medications.

  Recruiting Phase 2 Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida · Paris, Île-de-France Region · NCT06774872

• Long-acting Lenacapavir for treating HIV-1 in adolescents and children

  This study is testing a new long-acting HIV treatment called lenacapavir to see if it works better for adolescents and children who have had problems with their current medications.

  Recruiting at 8 sites Phase 2 Gilead Sciences · Atlanta, Georgia and 8 other locations · NCT06749054

• Best way to manage dolutegravir resistance in people with HIV

  This trial will test whether staying on dolutegravir or switching to darunavir/ritonavir better controls HIV in people with dolutegravir-resistant virus and a viral load of 200 copies/mL or higher.

  Recruiting at 2 sites Phase 3 University of Nairobi · Kisumu and 8 other locations · NCT06747507

• Using caspofungin to treat Pneumocystis pneumonia in people with HIV.

  This study is testing whether caspofungin can be a safer treatment for Pneumocystis pneumonia in people with HIV/AIDS compared to the usual medication.

  Recruiting Instituto Nacional de Enfermedades Respiratorias · Mexico City, Tlalpan · NCT06691321

• Therapy for HIV-positive individuals with hazardous drinking

  This study is testing if a new therapy combined with a short alcohol intervention can help people with HIV who drink too much to reduce their alcohol use and improve their overall health.

  Recruiting Syracuse University · Syracuse, New York · NCT06648629

• Tesamorelin plus exercise to improve physical function in older adults with HIV

  This trial will test whether adding the drug tesamorelin to a structured exercise program helps improve strength and physical performance in adults aged 50–80 living with HIV who have abdominal obesity and early frailty.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Aurora, Colorado and 1 other locations · NCT06554717

• Survey to assess eligibility for infectious disease clinical trials

  This study is trying to find out if people are eligible to join clinical trials for infectious diseases like HIV and vaccines by having them fill out a survey about their health and background.

  Recruiting Brooklyn Clinical Research · Brooklyn, New York · NCT06492187

• Providing ongoing access to HIV treatment for children and adolescents

  This study is testing whether children and teens with HIV can keep getting their treatment or switch to a new combination therapy to ensure they stay healthy.

  Recruiting at 13 sites Phase 4 Gilead Sciences · Buenos Aires and 16 other locations · NCT06337032

• Comparing doravirine and dolutegravir for treating HIV-1 in new patients

  This study is testing if a new HIV treatment called doravirine works just as well as the standard treatment dolutegravir for people who are starting their first HIV therapy.

  Recruiting at 18 sites Phase 3 ANRS, Emerging Infectious Diseases · Nova Iguaçu, Rio de Janeiro and 18 other locations · NCT06203132

• Monitoring HIV drug resistance and treatment strategies in Eastern Europe and Russia

  This study is trying to see how new HIV drugs work in people in Eastern Europe and Russia by looking at how drug resistance changes over time and how it affects treatment.

  Recruiting at 4 sites Euresist Network GEIE · Cologne and 3 other locations · NCT06127290

• Observing HIV control without medication

  This study looks at people who have been able to control their HIV without medication to see how they do it and what keeps them healthy.

  Recruiting at 4 sites Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · San Francisco, California and 3 other locations · NCT05985642

• Immuno-virological Evaluation of People Living with HIV

  This study will test immune and viral factors in two groups of people with HIV who have been on stable ART for different lengths of time.

  Recruiting University Hospital, Ghent · Ghent, Oost-Vlaanderen · NCT05973825

• Using Venetoclax to Target HIV-infected Cells in People on ART

  This study is testing if a drug called venetoclax can help people living with HIV who are on treatment by targeting and killing HIV-infected cells to see if it improves their immune function and reduces the virus in their bodies.

  Recruiting at 2 sites Phase 1/2 University of Aarhus · Melbourne, Melbourne and 1 other locations · NCT05668026

• Investigating the HIV Infected Reservoir to Find a Cure

  This study is trying to find ways to cure HIV by looking at the hidden virus in the blood of different groups of people living with HIV.

  Recruiting Erasmus Medical Center · Rotterdam · NCT05215704

• Investigating how depression treatment affects gut health and brain function in people with HIV

  This study is testing whether treating depression with therapy can improve gut health and brain function in people living with HIV.

  Recruiting at 2 sites Florida International University · Coral Gables, Florida and 1 other locations · NCT05136703

• Testing a two-pill HIV treatment for patients switching from triple therapy

  This study is testing if switching to a new two-pill HIV treatment can keep people with HIV healthy and undetectable after they’ve been on a stable three-pill regimen.

  Recruiting at 3 sites Phase 3 Chelsea and Westminster NHS Foundation Trust · London and 2 other locations · NCT04892654

• Using Semaglutide to Help People with HIV Lose Weight

  This study is testing if a weight loss medication called semaglutide can help people with HIV lose weight and improve their overall health.

  Recruiting University College Dublin · Dublin, Dublin · NCT04174755

• Registry of HIV-1 Patients with Drug Resistance

  This study is tracking people with HIV-1 who have drug resistance to see how different treatments work for them over time.

  Recruiting IRCCS San Raffaele · Milan, MI · NCT04098315

• Imaging of a Radiolabeled Antibody for HIV-1

  This study is testing a special imaging technique using a tiny dose of a radiolabeled antibody in people with HIV and healthy volunteers to see how it spreads in the body and if there are differences between the two groups.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT03729752

NIH-funded research (40)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• BEAT-HIV: a collaborative effort to cure HIV with immunotherapy

  A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.

  NIH research Wistar Institute · Philadelphia, United States · NIH-11515077

• Phosphatidylserine-targeting antibodies and T cell function in HIV-1 infection

  This NIH grant will explore how antibodies that target phosphatidylserine affect immune cells in people living with HIV on ART.

  NIH research Rutgers Biomedical and Health Sciences · Newark, UNITED STATES · NIH-11470783

• Ribosomal frameshifting in HIV-1 infection and its effects on inflammation and brain health

  A study at the University of Rochester will explore how HIV-1 may change human cell machinery to boost its own replication and cause inflammation and brain-related problems.

  NIH research University of Rochester · Rochester, United States · NIH-11421516

• Targeting NLRP3 inflammasome to protect HIV patients from stroke

  A small NIH grant will explore whether HIV infection makes stroke worse and whether blocking a brain inflammation pathway (NLRP3) could protect brain tissue.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11411011

• Reprogramming tissue immune cells (macrophages) to target hidden HIV

  Trying small drug molecules to reprogram tissue immune cells so infected cells die and hidden HIV is reduced in people living with HIV.

  NIH research Cornell University · Ithaca, United States · NIH-11394241

• EHD4 protein and HIV-1 infection: a new potential antiviral target

  A study to understand how the human protein EHD4 affects HIV-1 infection and whether it could be targeted to develop better antiviral therapies.

  NIH research State University of New York at Buffalo · Amherst, United States · NIH-11378780

• Understanding Brain Cell Growth in People with HIV and Methamphetamine Exposure

  This research explores how HIV and methamphetamine use together might change how new brain cells grow, aiming to understand related thinking problems.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11325939

• Elite controllers: learning how the body can cure HIV-1 naturally

  Researchers are studying people who naturally control HIV-1 without drugs to uncover clues for a functional cure that could help others live without daily therapy.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11320953

• How host +TIP proteins attach to HIV's capsid during early infection

  This project looks at whether certain human cell proteins called +TIPs attach to and change the HIV capsid during the virus's earliest steps, which might reveal new ways to block infection.

  NIH research Northwestern University · Chicago, United States · NIH-11310750

• How HIV and long-term HIV medicines affect brain circuits

  This project is mapping how HIV infection and long-term antiretroviral medicines may change brain activity linked to thinking and memory in people with HIV.

  NIH research State University New York Stony Brook · Stony Brook, United States · NIH-11263633

• How FEZ proteins help HIV move inside human cells

  This research looks at how proteins called FEZ help HIV travel inside human cells early after infection.

  NIH research Northwestern University · Chicago, United States · NIH-11231237

• Precision immune strategies to control HIV in babies and children

  Trying immune-based treatments in infants, children, and teens with HIV to help their immune systems control the virus and possibly reduce lifelong medicine needs.

  NIH research Harvard University D/b/a Harvard School of Public Health · Boston, United States · NIH-11178668

• Why some people naturally keep HIV under control

  This project looks at why a small group of people called elite controllers keep HIV at undetectable levels without treatment, to help develop ways to silence the virus for others living with HIV.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11163480

• Understanding and Treating Brain Disorders in People with HIV

  This work explores how a specific chemical byproduct might cause brain and nerve problems in people living with HIV, and tests new ways to reduce it.

  NIH research University of Nebraska Medical Center · Omaha, United States · NIH-11162450

• Understanding Gut Antibodies in HIV-1 Infection

  This project looks at how special antibodies in the gut might help people living with HIV-1 stay healthier.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11158681

• Understanding the body's early response to HIV-1

  This work explores how the body's natural defenses react right after HIV-1 infection to help develop better ways to prevent or treat the virus.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11145751

• Understanding why some people with HIV don't recover their immune cells

  This research explores how gut bacteria might prevent some people with HIV from fully restoring their immune system, even with treatment.

  NIH research Emory University · Atlanta, United States · NIH-11112499

• How HIV-1 infects CD4+ T cells through a process called macropinocytosis

  This study is looking at how HIV-1 gets into important immune cells called CD4+ T cells and how a special process called macropinocytosis helps with this, so we can find new ways to fight HIV/AIDS.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11109483

• Understanding how HIV-1 moves inside cells during early infection

  This study is looking at how the HIV virus moves inside cells to reach the nucleus, focusing on a special protein called FEZ1 that helps with this process, which could help us find new ways to treat HIV infections.

  NIH research Northwestern University at Chicago · Chicago, United States · NIH-11096170

• Understanding how HIV-1 infects cells

  This work aims to understand the very first steps of how the HIV-1 virus enters and infects human cells.

  NIH research Emory University · Atlanta, United States · NIH-11090336

• BEAT-HIV: Combination Treatments to Cure HIV-1 Infection

  This project looks for new ways to cure HIV-1 infection by combining different immune-boosting treatments.

  NIH research Wistar Institute · Philadelphia, United States · NIH-11080771

• Investigating how CARD8 inflammasome affects HIV-1 infection

  This study is looking at how a part of your immune system called CARD8 interacts with the HIV virus and how this could help us find better ways to treat people living with HIV by targeting hidden virus reservoirs.

  NIH research Washington University · Saint Louis, United States · NIH-11077212

• Effects of certain molecules on brain cell growth after methamphetamine use and HIV infection

  This study is looking at how methamphetamine and HIV might affect the growth of new brain cells in adults, especially by exploring the role of certain molecules that help move brain cells around, with the hope of finding new ways to help people with HIV who also use meth.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11057620

• Investigating how certain proteins interact with HIV-1 during early infection

  This study is looking at how certain proteins in our bodies interact with the HIV virus in its early stages, which could help scientists find new ways to treat HIV and improve care for patients.

  NIH research Northwestern University at Chicago · Chicago, United States · NIH-11017810

• Investigating how HIV-1 infection and antiretroviral therapy affect brain function

  This study is looking at how HIV-1 infection and the treatment for it can affect thinking and memory by using special imaging techniques on mice to see how their brains work, which could help us understand similar challenges in people living with HIV.

  NIH research State University New York Stony Brook · Stony Brook, United States · NIH-11010369

• Understanding how the immune system detects HIV-1 infection

  This study is looking at how the body's first line of defense reacts to HIV-1 right after infection, using special mice to help understand which immune cells are involved, and the findings could help improve vaccines and treatments for people living with HIV.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11009442

• Investigating neurological disorders in people living with HIV

  This study is looking at how a substance related to sugar breakdown might affect brain health in middle-aged people with HIV, using mice to see if lowering this substance can help improve their symptoms.

  NIH research University of Nebraska Medical Center · Omaha, United States · NIH-11008730

• Understanding how antibodies interact with the gut microbiome in HIV-1 infection

  This study is looking at how a type of antibody called IgA helps keep the gut healthy for people living with HIV-1, by comparing gut samples from those with and without the virus to see how these antibodies work with gut bacteria and affect overall health.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-10918746

• Exploring new ways to control HIV-1 infection in children

  This study is exploring new ways to help kids and teens with HIV-1 by boosting their immune systems to better control the virus, aiming for a functional cure that doesn't require completely getting rid of it.

  NIH research Harvard School of Public Health · Boston, United States · NIH-10914864

• Understanding how elite controllers manage HIV-1 infection without treatment

  This study is looking at a special group of people called elite controllers who can keep HIV-1 at very low levels without any medication, and by exploring their unique genetics, we hope to find new ways to help others with HIV-1 manage the virus better or even find a cure.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-10911776

• Investigating lung cancer risks in people with HIV-1 in Uganda and Tanzania

  This study is looking at how being infected with HIV-1 might increase the chances of getting lung cancer, especially in Uganda and Tanzania, and it wants to find out what other factors, like smoking and the environment, play a role so that we can come up with better ways to prevent and catch lung cancer early for peopl

  NIH research Case Western Reserve University · Cleveland, United States · NIH-10904978

• Investigating lung cancer and its link to HIV-1 in East Africa

  This study is looking at how lung cancer and HIV-1 infection are connected in East Africa, aiming to improve how lung cancer is diagnosed and treated, especially for those who might also have tuberculosis, so that patients can get the right care they need.

  NIH research Case Western Reserve University · Cleveland, United States · NIH-10904973

• Understanding how cannabinoids affect HIV-1 infection and inflammation

  This study is looking at how cannabinoids might help reduce inflammation in people living with HIV by exploring their effects on certain immune cells, and it aims to find new ways to manage inflammation even when HIV treatment is working.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-10889168

• Finding a cure for HIV-1 infection through mentoring

  This study is all about helping new scientists and doctors learn how to conduct research that could lead to better treatments for HIV, using real patient cells to find new ways to fight the virus.

  NIH research Brigham and Women's Hospital · Boston, United States · NIH-10877808

• Understanding heart failure in people with HIV-1 infection

  This study is looking at how a harmful substance in the body might lead to heart problems in people with long-term HIV, and it hopes to find new ways to help treat these heart issues.

  NIH research University of Nebraska Medical Center · Omaha, United States · NIH-10875565

• New methods to improve immune cell functions for clearing HIV-1 infection

  This study is looking at how certain antibodies can help your immune system better fight off HIV-infected cells while you're on treatment, with the hope of finding new ways to help people with HIV live healthier lives.

  NIH research Washington University · Saint Louis, United States · NIH-10872269

• Investigating how masculinizing hormone therapy affects HIV-1 risk in transgender men

  This study is looking at how testosterone therapy affects transgender men and whether it changes their risk of getting HIV, helping us learn more about their sexual health and safety.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-10865047

• Investigating how HIV drugs cross the blood-brain barrier

  This study is looking at how well certain HIV medications can get into the brain to fight the virus, with the goal of finding better ways to help people living with HIV-1.

  NIH research University of Colorado · Boulder, UNITED STATES · NIH-10838759

• Investigating how different injectable contraceptives affect HIV-1 infection risk in women.

  This study is looking at how two types of birth control shots might affect the risk of getting HIV-1 in young women in sub-Saharan Africa, so we can better understand their safety and help keep women healthy.

  NIH research University of Cape Town · Rondebosch, South Africa · NIH-10815728

• Tracking HIV treatment effects in the brain using advanced imaging techniques

  This study is looking at how HIV medications affect the brain using a special type of MRI that can see important brain chemicals, helping us understand how these drugs work and improve brain health for people living with HIV.

  NIH research University of Nebraska Medical Center · Omaha, United States · NIH-10761339

Related topics

Quick answers

How many HIV-1-infection clinical trials are recruiting right now?

41, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 31 countries. The most sites are in United States (22 trials), South Africa (4 trials), Italy (3 trials), Germany (3 trials), Argentina (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7, Phase 1: 6, Phase 4: 6, Phase 3: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →